ClinicalTrials.gg
TerminatedNCT06400303Updated Aug 31, 2026

KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis

A Phase 1/2 interventional study of KYV-101 and Standard lymphodepletion regimen in Systemic Sclerosis, Systemic Sclerosis - Diffuse Cutaneous and Systemic Sclerosis - 2013 ACR/EULAR Classification Criteria, sponsored by Kyverna Therapeutics. Terminated at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-31.

Sponsored by Kyverna Therapeutics · Phase 1/2, Interventional, and Treatment

How we know

Why this study was terminated
Study discontinued due to sponsor decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
3
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 165 studies in Scleroderma, Systemic with a site in United States — 40 open to participants now, 52 under way, 6 of them phase 3. Scleroderma, Systemic · United States.

Enrollment
136th of 142
3 · median 34
Started
2024
with 9 others
Phase 1/2
15 of 165
4 open now
Registered
122nd of 165
by date

Among the 165 studies in Scleroderma, Systemic with a site in United States, this one is the 136th largest by enrollment of the 142 interventional ones that give a count, is one of 10 that started in 2024, is one of 15 in phase 1/2, and was the 122nd registered.

Scleroderma, Systemic

614 studies on the registry are indexed under Scleroderma, Systemic; 222 are open to participants now.

Browse Scleroderma, Systemic studies →

Open to participants now

40 of the 165 studies in Scleroderma, Systemic with a site in United States are open now. Recruiting first, the newest first:

35 more — sign in →

All 40 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 147 Scleroderma, Systemic studies recruiting now, 85 (58%) set no upper age limit and 49 (33%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 165 studies in Scleroderma, Systemic with a site in United States, or all of them as a file.
02

Study summary

A Study of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy for Subjects with Systemic Sclerosis

Read the detailed description

SSc is an immune-mediated rheumatic disease that is characterized by fibrosis of the skin and internal organs and vasculopathy. B-cells play a role in SSc, and the disease is characterized by the presence of autoantibodies such as anti-Scl-70 and anti-RNAP III antibodies. CD19-targeted chimeric antigen receptor (CAR) T-cells harness the ability of cytotoxic T-cells to directly and specifically lyse target cells to effectively deplete B-cells in the circulation and in lymphoid and potentially non-lymphoid tissues. KYV-101, a fully human anti-CD19 CAR T-cell therapy, will be investigated in adult subjects with systemic sclerosis.

03

Conditions studied

  • Systemic Sclerosis
  • Systemic Sclerosis - Diffuse Cutaneous
  • Systemic Sclerosis - 2013 ACR/EULAR Classification Criteria

Keywords

  • KYV-101
  • systemic sclerosis
  • autoimmune disease
  • anti-CD19 CAR-T therapy
  • cellular therapy
  • Scleroderma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria

  1. Clinical diagnosis of SSc according to 2013 ACR/EULAR classification
  2. Clinical disease as follows: Classified as diffuse cutaneous SSc; ≤ 6 years since first non-Raynaud's sign or symptom; active disease
  3. Up to date on all recommended vaccinations per CDC or institutional guidelines for immune-compromised individuals

Key Exclusion Criteria

  1. ILD
  2. Prior treatment with cellular therapy (CAR-T) or gene therapy product directed at any target
  3. History of or autologous stem cell transplant
  4. Evidence of active or infection
  5. Positive serology for
  6. Primary immunodeficiency
  7. History of splenectomy
  8. History of stroke, seizure, dementia, Parkinson's disease, coordination movement disorder, cerebellar diseases, psychosis, paresis, aphasia, and any other neurologic disorder investigator considers would increase the risk for the subject
  9. Impaired cardiac function or clinically significant cardiac disease
  10. Previous or concurrent with the following exceptions:

    1. Adequately treated basal cell or squamous cell carcinoma (adequate wound healing is required prior to screening)
    2. In situ carcinoma of the cervix or breast, treated curatively and without evidence of recurrence for at least 3 years prior to screening
    3. A primary malignancy which has been completely resected, or treated, and is in complete remission for at least 5 years prior to screening
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
3 participants (actual)

Study arms

  • Experimental
    KYV-101 CAR-T cells with lymphodepletion conditioning (Phase 1)

    Dosing with KYV-101 CAR T cells

    Biological: KYV-101 · Drug: Standard lymphodepletion regimen

  • Experimental
    KYV-101 CAR-T cells with lymphodepletion conditioning (Phase 2)

    Recommended Phase 2 Dose

    Biological: KYV-101 · Drug: Standard lymphodepletion regimen

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events and laboratory abnormalities (Phase 1)

    Time frame: Up to 2 years

  2. Frequency of Dose-Limiting Toxicities (DLTs) at each dose level (Phase 1)

    Time frame: Up to 2 years

  3. To evaluate efficacy of KYV-101(Phase 2)

    via revised Composite Response Index in Systemic Sclerosis (rCRISS) 30/5

    Time frame: 52 weeks

Secondary outcomes

  1. To evaluate pharmacodynamics (PK) of KYV-101 in blood (Phase 1 and Phase 2)

    Chimeric antigen receptor-positive (CAR-positive) T-cell counts in blood

    Time frame: Up to 2 years

  2. To evaluate pharmacodynamics (PD) of KYV-101 in blood (Phase 1 and Phase 2)

    Levels of B-cells in blood

    Time frame: Up to 2 years

  3. To evaluate pharmacodynamics (PD) of KYV-101 in blood (Phase 1 and Phase 2)

    Levels of cytokines in serum

    Time frame: Up to 2 years

  4. To evaluate efficacy of KYV-101 (Phase 1 and Phase 2)

    revised Composite Response Index in Systemic Sclerosis (rCRISS) 30/5 response rate

    Time frame: 12, 24, 52 weeks

  5. To evaluate immunogenicity (humoral response) of KYV-101 (Phase 1 and Phase 2)

    Percentage of participants who develop anti-KYV-101 antibodies by immunoassays

    Time frame: Up to 2 years

  6. To define the Recommended Phase 2 Dose (RP2D) (Phase 1)

    Time frame: Up to 2 years

07

Study locations

2 sites
  • Stanford University Medical Center
    Palo Alto, California 94305, United States
  • Northwell Health
    Great Neck, New York 11021, United States
08

References and documents

Publications

  • Bosello S, Angelucci C, Lama G, Alivernini S, Proietti G, Tolusso B, Sica G, Gremese E, Ferraccioli G. Characterization of inflammatory cell infiltrate of scleroderma skin: B cells and skin score progression. Arthritis Res Ther. 2018 Apr 18;20(1):75. doi: 10.1186/s13075-018-1569-0. PubMed 29669578 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2024 to primary completion in Jun 2026, 22 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2023
First posted
May 6, 2024
StartActual
Aug 6, 2024
Primary completionActual
Jun 16, 2026
CompletionActual
Jun 16, 2026
Last update
Aug 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06400303
Lead sponsor
Kyverna Therapeutics
Responsible party
Sponsor
First posted
May 6, 2024
Start date
Aug 6, 2024
Primary completion
Jun 16, 2026
Completion
Jun 16, 2026
Last update
Aug 31, 2026

Study contacts

MD
study director · Kyverna Therapeutics, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mivocabtagene autoleucel

Start the discussion